eli lilly news glp-1 FDA just approved orforglipron (Foundayo), Lilly's oral receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest Drugmaker Eli Lilly has released

MEDVi emphasizes open communication between patient and provider, with telehealth check-ins and dosage management to maintain safety throughout treatment

This long half-life provides the widest flexibility window for early dosing

"It's good news that Medicare is rolling out this program, but it is temporary, so it's really not clear at this point what happens after the end of the 18-month program duration," said Juliette Cubanski, director of the Program on Medicare Policy at KFF, a health policy research organization

We provide continuous support, including nutritional counseling and lifestyle recommendations, to complement the medications effects